Rémy Choquet1, Meriem Maaroufi1, Albane de Carrara2, Claude Messiaen2, Emmanuel Luigi3, Paul Landais4. 1. BNDMR, Assistance Publique Hôpitaux de Paris, Hôpital Necker Enfants Malades, Paris, France INSERM, U1142, LIMICS, Paris, France. 2. BNDMR, Assistance Publique Hôpitaux de Paris, Hôpital Necker Enfants Malades, Paris, France. 3. Direction Générale de l'Offre de Soins, Ministère de la Santé et de la Solidarité, Paris, France. 4. BNDMR, Assistance Publique Hôpitaux de Paris, Hôpital Necker Enfants Malades, Paris, France Faculty of Medicine, EA2415, Clinical Research University Institute, Montpellier 1 University and BESPIM, Nîmes University Hospital, France.
Abstract
BACKGROUND: Although rare disease patients make up approximately 6-8% of all patients in Europe, it is often difficult to find the necessary expertise for diagnosis and care and the patient numbers needed for rare disease research. The second French National Plan for Rare Diseases highlighted the necessity for better care coordination and epidemiology for rare diseases. A clinical data standard for normalization and exchange of rare disease patient data was proposed. The original methodology used to build the French national minimum data set (F-MDS-RD) common to the 131 expert rare disease centers is presented. METHODS: To encourage consensus at a national level for homogeneous data collection at the point of care for rare disease patients, we first identified four national expert groups. We reviewed the scientific literature for rare disease common data elements (CDEs) in order to build the first version of the F-MDS-RD. The French rare disease expert centers validated the data elements (DEs). The resulting F-MDS-RD was reviewed and approved by the National Plan Strategic Committee. It was then represented in an HL7 electronic format to maximize interoperability with electronic health records. RESULTS: The F-MDS-RD is composed of 58 DEs in six categories: patient, family history, encounter, condition, medication, and questionnaire. It is HL7 compatible and can use various ontologies for diagnosis or sign encoding. The F-MDS-RD was aligned with other CDE initiatives for rare diseases, thus facilitating potential interconnections between rare disease registries. CONCLUSIONS: The French F-MDS-RD was defined through national consensus. It can foster better care coordination and facilitate determining rare disease patients' eligibility for research studies, trials, or cohorts. Since other countries will need to develop their own standards for rare disease data collection, they might benefit from the methods presented here.
BACKGROUND: Although rare disease patients make up approximately 6-8% of all patients in Europe, it is often difficult to find the necessary expertise for diagnosis and care and the patient numbers needed for rare disease research. The second French National Plan for Rare Diseases highlighted the necessity for better care coordination and epidemiology for rare diseases. A clinical data standard for normalization and exchange of rare disease patient data was proposed. The original methodology used to build the French national minimum data set (F-MDS-RD) common to the 131 expert rare disease centers is presented. METHODS: To encourage consensus at a national level for homogeneous data collection at the point of care for rare disease patients, we first identified four national expert groups. We reviewed the scientific literature for rare disease common data elements (CDEs) in order to build the first version of the F-MDS-RD. The French rare disease expert centers validated the data elements (DEs). The resulting F-MDS-RD was reviewed and approved by the National Plan Strategic Committee. It was then represented in an HL7 electronic format to maximize interoperability with electronic health records. RESULTS: The F-MDS-RD is composed of 58 DEs in six categories: patient, family history, encounter, condition, medication, and questionnaire. It is HL7 compatible and can use various ontologies for diagnosis or sign encoding. The F-MDS-RD was aligned with other CDE initiatives for rare diseases, thus facilitating potential interconnections between rare disease registries. CONCLUSIONS: The French F-MDS-RD was defined through national consensus. It can foster better care coordination and facilitate determining rare disease patients' eligibility for research studies, trials, or cohorts. Since other countries will need to develop their own standards for rare disease data collection, they might benefit from the methods presented here.
Authors: P David Adelson; Jose Pineda; Michael J Bell; Nicholas S Abend; Rachel P Berger; Christopher C Giza; Gillian Hotz; Mark S Wainwright Journal: J Neurotrauma Date: 2011-11-07 Impact factor: 5.269
Authors: Yaffa R Rubinstein; Stephen C Groft; Sara Hull Chandros; Julie Kaneshiro; Barbara Karp; Nicole C Lockhart; Patricia A Marshall; Richard T Moxley; Geraldine B Pollen; Vanessa Rangel Miller; Jack Schwartz Journal: Contemp Clin Trials Date: 2011-10-24 Impact factor: 2.226
Authors: H Vernon Anderson; William S Weintraub; Martha J Radford; Mark S Kremers; Matthew T Roe; Richard E Shaw; Dana M Pinchotti; James E Tcheng Journal: J Am Coll Cardiol Date: 2013-03-06 Impact factor: 24.094
Authors: Nancy S Redeker; Ruth Anderson; Suzanne Bakken; Elizabeth Corwin; Sharron Docherty; Susan G Dorsey; Margaret Heitkemper; Donna Jo McCloskey; Shirley Moore; Carol Pullen; Bruce Rapkin; Rachel Schiffman; Drenna Waldrop-Valverde; Patricia Grady Journal: J Nurs Scholarsh Date: 2015-08-06 Impact factor: 3.176